Fibrosarcoma cells expressing allogeneic MHC Class II antigens induce protective antitumor immunity
- PMID: 7814880
Fibrosarcoma cells expressing allogeneic MHC Class II antigens induce protective antitumor immunity
Abstract
The initiation of effective immune responses usually requires presentation of Ags by MHC class I and class II molecules. Although most tumors express MHC class I molecules, MHC class II molecule expression is generally limited to specialized APCs. One reason spontaneous tumors may fail to elicit effective immune responses is that tumor Ags are inefficiently presented by APCs, and adequate T cell-mediated help is not generated. To test this hypothesis, we investigated the possibility of enhancing Th cell stimulation by inducing expression of MHC class II molecules on tumor cells. We transfected a murine fibrosarcoma, Sa1N, with the genes encoding allogeneic (I-Ad) or syngeneic (I-Ak) MHC class II molecules. We then compared the tumorigenic and immunogeneic potential of these transfectants to parental Sa1N tumor cells. Subcutaneous injection of allogeneic or syngeneic transfectants resulted in dramatically fewer tumors than injection of unmodified fibrosarcoma cells, and mice inoculated with MHC class II gene-transfected cells were resistant to subsequent challenge with parental Sa1N cells. Rejection of allogeneic MHC class II Ag+ tumor cells could be mediated by either CD4+ or CD8+ T cells, whereas rejection of secondary challenge with wild-type Sa1N tumor cells required both T cell subsets. These results demonstrate that allogeneic, as well as syngeneic, MHC class II Ag+ tumor cells can stimulate protective antitumor immunity.
Similar articles
-
Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2.J Immunol. 1993 Jul 1;151(1):244-55. J Immunol. 1993. PMID: 8326126
-
Rejection of mouse sarcoma cells after transfection of MHC class II genes.J Immunol. 1990 May 15;144(10):4068-71. J Immunol. 1990. PMID: 2332639
-
Tumor cells engineered to express major histocompatibility complex class II molecules induce T helper cell-dependent responses that protect mice from normally lethal doses of unmodified tumor cells.Cancer Detect Prev. 1996;20(3):199-206. Cancer Detect Prev. 1996. PMID: 8769713
-
Bacterial antigen delivery systems: phagocytic processing of bacterial antigens for MHC-I and MHC-II presentation to T cells.Behring Inst Mitt. 1997 Feb;(98):197-211. Behring Inst Mitt. 1997. PMID: 9382741 Review.
-
Turning tumor cells in situ into T-helper cell-stimulating, MHC class II tumor epitope-presenters: immuno-curing and immuno-consolidation.Cancer Treat Rev. 2004 May;30(3):281-90. doi: 10.1016/j.ctrv.2003.08.002. Cancer Treat Rev. 2004. PMID: 15059651 Review.
Cited by
-
Identification of a novel PD-L1 positive solid tumor transplantable in HLA-A*0201/DRB1*0101 transgenic mice.Oncotarget. 2017 Jul 25;8(30):48959-48971. doi: 10.18632/oncotarget.16900. Oncotarget. 2017. PMID: 28430664 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous